ANTIPODES PARTNERS Ltd Acquires 889,229 Shares of Globus Medical, Inc. $GMED

ANTIPODES PARTNERS Ltd raised its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 49,020.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 891,043 shares of the medical device company’s stock after purchasing an additional 889,229 shares during the period. ANTIPODES PARTNERS Ltd owned 0.66% of Globus Medical worth $51,034,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Burgundy Asset Management Ltd. increased its position in Globus Medical by 24.3% during the 2nd quarter. Burgundy Asset Management Ltd. now owns 3,481,438 shares of the medical device company’s stock valued at $205,474,000 after buying an additional 679,691 shares in the last quarter. Sculptor Capital LP grew its stake in shares of Globus Medical by 31.9% in the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock worth $162,936,000 after acquiring an additional 667,850 shares during the last quarter. Geneva Capital Management LLC grew its stake in shares of Globus Medical by 13.6% in the second quarter. Geneva Capital Management LLC now owns 2,082,788 shares of the medical device company’s stock worth $122,926,000 after acquiring an additional 249,141 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Globus Medical by 89.7% during the second quarter. Marshall Wace LLP now owns 1,580,476 shares of the medical device company’s stock valued at $93,280,000 after acquiring an additional 747,330 shares in the last quarter. Finally, AXA S.A. raised its position in shares of Globus Medical by 9.0% in the 2nd quarter. AXA S.A. now owns 1,528,531 shares of the medical device company’s stock worth $90,214,000 after purchasing an additional 126,326 shares during the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Citigroup reissued a “market perform” rating on shares of Globus Medical in a research report on Thursday, January 8th. Wells Fargo & Company upped their target price on shares of Globus Medical from $66.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Royal Bank Of Canada increased their price target on shares of Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. BTIG Research restated a “neutral” rating on shares of Globus Medical in a report on Tuesday, December 30th. Finally, Stifel Nicolaus initiated coverage on Globus Medical in a research report on Tuesday, October 28th. They issued a “hold” rating and a $64.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.18.

Insider Buying and Selling

In other Globus Medical news, Director Leslie V. Norwalk sold 2,000 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the completion of the sale, the director owned 10,419 shares in the company, valued at $1,053,360.90. This represents a 16.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Kelly Huller sold 10,000 shares of Globus Medical stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $87.67, for a total value of $876,700.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 41,636 shares of company stock valued at $3,786,033. 18.51% of the stock is owned by insiders.

Globus Medical Trading Down 0.4%

NYSE:GMED opened at $90.58 on Friday. The company has a 50 day simple moving average of $89.84 and a two-hundred day simple moving average of $75.02. The company has a market cap of $12.12 billion, a PE ratio of 29.22, a price-to-earnings-growth ratio of 1.39 and a beta of 1.06. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.